Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. KBL Merger Corp IV Warrant 2017-15.01.24 on KBL Merger IV
KBLMW

Buy KBLMW Stock

KBLMW
See KBLMW stock price and Buy/Sell KBL Merger Corp IV Warrant 2017-15.01.24 on KBL Merger IV with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
KBLMW

KBL Merger Corp IV Warrant 2017-15.01.24 on KBL Merger IV (KBLMW)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About KBL Merger Corp IV Warrant 2017-15.01.24 on KBL Merger IV (KBLMW)

180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. It operates as a clinical-stage biotechnology company focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The c...Read more
Market Cap
1 Year High
Volume
6.2k
1 Year Low
Price to Earnings Ratio
Open
$0.27
Dividend Rate
High
$0.27
Dividend Yield
Low
$0.27

Community

People who own or watch KBLMW stock

KBLMW stock rating

What analysts recommend for KBLMW stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell

KBLMW price target

What analysts think KBLMW will be worth
Low $0
High $0.27
Current $0.27
Target $0

Buy KBLMW Stock

KBLMW
See KBLMW stock price and Buy/Sell KBL Merger Corp IV Warrant 2017-15.01.24 on KBL Merger IV with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch KBLMW stock
  • bryantangie avatar
  • christopher0713 avatar
  • sexyp avatar
  • Tillablechild avatar
  • NicoleColess avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.